Drug Type Small molecule drug |
Synonyms (+)-ampelopsin, (+)-dihydromyricetin, Ampelopsin + [2] |
Target |
Action inhibitors |
Mechanism PB2 inhibitors(polymerase basic protein 2 (PB2) inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC15H12O8 |
InChIKeyKJXSIXMJHKAJOD-LSDHHAIUSA-N |
CAS Registry27200-12-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 2 | Phase 2 | Mexico | 30 Oct 2019 | |
Alcohol-Related Disorders | Phase 1 | United States | 15 Sep 2024 | |
Liver Diseases, Alcoholic | Phase 1 | United States | 15 Sep 2024 | |
Influenza, Human | Preclinical | China | 01 Jul 2020 |
Not Applicable | - | Dihydromyricetin (DHM) | enyimsgohb(oqbbfdhvnx) = mkkqdwnxeg vsajcnshjx (egtfmyzvxz ) View more | - | 17 Oct 2012 | ||
Ethanol (20E) | enyimsgohb(oqbbfdhvnx) = wrwfjirbys vsajcnshjx (egtfmyzvxz ) View more |